Kaposi’s sarcoma in HIV-negative patient with primary myelofibrosis
E. K. Egorova,
A. L. Melikyan,
I. N. Subortseva,
E. A. Domonova,
O. Y. Silveystrova,
D. I. Chebotarev,
A. M. Kovrigina https://doi.org/10.35754/0234-5730-2021-66-3-433-444
Abstract
Introduction. Kaposi’s sarcoma (КS) is a multi-focal malignant tumor of vascular origin with a predominant lesion of the skin, involving internal organs and lymph nodes. Epidemic and immunosuppressive variants of the disease are considered to be the most studied and common. The main reason for the development of the immunosuppressive variant is the use of immunosuppressive drugs in patients after transplantation of solid organs. Descriptions of the development of Kaposi’s sarcoma in patients with diseases of the hematopoietic system are rare.
Aim — to describe a rare combination of a malignant tumor of vascular origin (Kaposi’s sarcoma) and a chronic myeloproliferative disease: primary myelofibrosis.
Main findings. To verify the diagnosis of Kaposi’s sarcoma in a patient with primary myelofibrosis, the following were used: histological, immunohistochemical studies of skin biopsies and the polymerase chain reaction method with detection of a fl uorescent signal in “real time” in biological material samples (peripheral blood, smear from the mucous membrane of the oropharynx, skin biopsies from lesions) with quantitative determination of the activity of the human herpes virus 8. A comprehensive examination made it possible to establish the final diagnosis of multiple malignant neoplasms and recommend treatment.
About the Authors
E. K. Egorova
National Research Center for Hematology
Russian Federation
Russian Federation
Elena K. Egorova*, Cand. Sci. (Med.), Hematologist at the Department of Standartization of Treatment Methods
125167, Moscow
A. L. Melikyan
National Research Center for Hematology
Russian Federation
Russian Federation
Anait L. Melikyan, Dr. Sci. (Med.), Head of the Department of Standartization of Treatment Methods
125167, Moscow
I. N. Subortseva
National Research Center for Hematology
Russian Federation
Russian Federation
Irina N. Subortseva, Cand. Sci. (Med.), Researcher, Oncologist at the Department of Standartization of Treatment Methods
125167, Moscow
E. A. Domonova
Central Research Institute of Epidemiology, the Federal Service for Surveillance on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
Elvira A. Domonova, Cand. Sci. (Biol.), Senior Researcher at the Department of Molecular Diagnostics and Epidemiology, Central Research Institute of Epidemiology
111123, Moscow
O. Y. Silveystrova
Central Research Institute of Epidemiology, the Federal Service for Surveillance on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
Olga Yu. Silveystrova, Junior Researcher at the Department of Molecular Diagnostics and Epidemiology, Central Research Institute of Epidemiology
111123, Moscow
D. I. Chebotarev
National Research Center for Hematology
Russian Federation
Russian Federation
Dmitry I. Chebotarev, Pathologist at the Pathology Department
125167, Moscow
A. M. Kovrigina
National Research Center for Hematology
Russian Federation
Russian Federation
Alla M. Kovrigina, Dr. Sci. (Biol.), Head of the Pathology Department
125167, Moscow
References
1. Basalely D., Khan K.H., Cavazos G.J., et al. Pedal presentation of Kaposi’s sarcoma in a non-HIV Hispanic female: A case report and literature review. J Foot Ankle Surg. 2012; 51(3): 365–8. DOI: 10.1053/j.jfas.2012.01.012.
2. Chang Y., Cesarman E., Pessin M.S., et al. Identifi cation of herpesviruslike DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994; 266(5192): 1865–9. DOI: 10.1126/science.7997879.
3. Orenstein J.M., Alkan S., Blauvelt A., et al. Visualization of human herpesvirus type 8 in Kaposi’s sarcoma by light and transmission electron microscopy. AIDS. 1997; 11(5): 35–45. DOI: 10.1097/00002030-199705000-00001.
4. Renne R., Lagunoff M., Zhong W., et al. The size and conformation of Kaposi’s sarcoma- associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol. 1996; 70(11): 8151–4. DOI: 10.1128/JVI.70.11.8151-8154.1996.
5. Kadyrova E., Lacoste V., Duprez R., et al. Molecular epidemiology of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 strains from Russian patients with classic, posttransplant, and AIDS-associated Kaposi’s sarcoma. J Med Virol. 2003; 71(4): 548–56. DOI: 10.1002/jmv.10530.
6. Gurtsevich V.E., Yakovleva L.S., Galetskiy S.A., et al. Clinical and virological characteristics of diseases associated with Kaposi’s sarcoma virus. Infectsiya I Immunitet. 2011; 1(2): 151–160. (in Russian).
7. Hu J., Renne R. Characterization of the minimal replicator of Kaposi’s sarcoma-associated herpesvirus latent origin. J Virol. 2005; 79(4): 2637–42. DOI: 10.1128/JVI.79.4.2637-2642.2005.
8. Du M.Q., Bacon C.M., Isaacson P.G. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007; 60(12): 1350–7. DOI: 10.1136/jcp.2007.047969.
9. Melikyan A.L., Egorova E.K., Julhakyan H.L., Kovrigina A.M. Human herpesvirus type 8 positive multicentric Castleman disease. Clin Lymphoma Myeloma Leuk. 2016; 16(Suppl): S159–65. DOI: 10.1016/j.clml.2016.03.009.
10. Melikyan A.L., Egorova E.K., Kovrigina А.М., et al. Clinical and morphological features of various variants of Castleman’s disease. Terapevticheskiy arckhiv.2015; 87: 64–71. DOI: 10.17116/terarkh201587764-71. (in Russian).
11. Cai Q., Verma S.C., Lu J., et al. Molecular biology of Kaposi’s sarcoma herpesvirus and related oncogenesis. Adv Virus Res. 2010; 78: 87–142. DOI: 10.1016/B978-0-12-385032-4.00003-3.
12. Sakakibara S., Tosato G. Viral interleukin-6: role in Kaposi’s sarcoma-associated herpesvirus-associated malignancies. J Interferon Cytokine Res. 2011; 31(11):791–801. DOI: 10.1089/jir.2011.0043.
13. Soulier J., Grollet L., Oksenhendler E., et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995: 86(4): 1276–80.
14. Plancoulaine S., Abel L., van Beveren M., et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet. 2000; 356(9235): 1062–5. DOI: 10.1016/S0140-6736(00)02729-X.
15. Brayfi eld B.P., Kankasa C., West J.T., et al. Distribution of Kaposi sarcomaassociated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: Implications for transmission. J Infect Dis. 2004; 189(12): 2260–70. DOI: 10.1086/421119.
16. Butler L.M., Were W.A., Balinandi S., et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis. 2011; 203(5): 625–34. DOI: 10.1093/infdis/jiq092.
17. Ablashi D.V., Chatlynne L.G., Whitman J.E. Jr., Cesarman E. Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev. 2002; 15(3): 439–64. DOI: 10.1128/cmr.15.3.439-464.2002.
18. Martin J.N. Epidemiology of Kaposi’s sarcoma-associated herpesvirus infection. In: Volberding P.A., Palevsky J.M., Walsh C.C. (eds). Viral and immunological malignancies. Hamilton: BC Decker Inc; 2006: 67–88.
19. Akasbi Y., Awada A., Arifi S., et al. Non-HIV Kaposi’s sarcoma: A review and therapeutic perspectives. Bull Cancer. 2012; 99(10): 93–9. DOI: 10.1684/bdc.2012.1636.
20. Sapozhnikov A.D., Perlina A.D., Dymkov I.N. Regression of Kaposi’s sarcoma after prolonged treatment with m-TOR inhibitors and complete cancellation of immunosuppression in the recipient after kidney transplantation. Vestnik transplantologii i iskusstvennykh organov. 2019; 21(2): 121–4. DOI: 10.15825/1995-1191-2019-2-121-124. (in Russian).
21. Vatazin A.V., Molochkov V.A., Kazantseva I.A., et al. Kaposi’s sarcoma in patients after kidney transplantation (experience of one center). Nefrologiya i dializ.1999; 1(2, 3): 155–63. (in Russian).
22. Heyrman B., De Becker A., Schots R. A case report of immunosuppressionrelated Kaposi’s sarcoma after autologous stem cell transplantation. BMC Res Notes. 2016; 9: 188. DOI: 10.1186/s13104-016-1991-9.
23. Campione E., Diluvio L., Paternò E.J., et al. Kaposi’s sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia. Clin Ther. 2009; 31(11): 2565–9. DOI: 10.1016/j.clinthera.2009.11.018.
24. Omine T., Yamaguchi S., Yasumura R., et al. Iatrogenic Kaposi’s sarcoma in a myelofi brosis patient treated with ruxolitinib. J Dermatol. 2020; 47(4): e131–2. DOI: 10.1111/1346-8138.15259.
25. Loscocco G.G., Vannucchi M., Paoli C., et al. Kaposi sarcoma in a patient treated with ruxolitinib. Ann Oncol. 2017; 28(7): 1670–1. DOI: 10.1093/annonc/mdx188.
26. Wani G.M., Ahmad S.M., Qayoom S., et al. Corticosteroid induced, HHV-8 positive Kaposi’s sarcoma in a non-HIV elderly patient. J IMA. 2012; 44(1): 44-1-9317. DOI: 10.5915/44-1-9317.
27. Endo G., Nagata N. Corticosteroid-induced Kaposi’s sarcoma revealed by severe anemia: A case report and literature review. Intern Med. 2019; 59(5): 625–31. DOI: 10.2169/internalmedicine.3394-19.
28. WHO Classifi cation of tumours of lymphoid and hematopoietic tissues. Lyon: IARC; 2017: 585.
29. Passamonti F., Cervantes F., Vannucchi A.M., et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofi brosis. Blood. 2010; 116(15): 2857–8. DOI: 10.1182/blood-2010-06-293415.
30. Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.S., et al. National clinical recommendations on diagnosis and treatment of multiple myeloma. Gematologiya i transfusiologiya. 2016; 61(1, Suppl. 2): 1–24. DOI: 10.18821/0234-5730-2016-61-1. (In Russian).
31. Melikyan A.L., Turkina A.G., Kovrigina A.M., et al. Clinical guidelines for the diagnosis and treatment of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofi brosis) (edition 2016). Gematologiya i transfuziologiya. 2017; 62(1, Suppl. 1): 1–60. (In Russian).
32. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph. 1872; 4(0): 265–73.
33. Volf K., Goldsmit L.A., Kats S.I., et al. Fitzpatrick’s Dermatology in Clinical Practice. Transl. from English. Vol. 2. Moscow: BINOM; 2012: 1838. (In Russian).
34. Kalamkaryan A.A., Akimov V.G., Kazanceva I.A. Kaposi’s sarcoma. Novosibirsk: Nauka; 1986: 111. (In Russian).
35. Lamotkin I.A. Tumors and tumor-like skin lesions: Atlas. Moscow: BINOM; 2006: 166. (In Russian).
Review
For citations:
Egorova E.K., Melikyan A.L., Subortseva I.N., Domonova E.A., Silveystrova O.Y., Chebotarev D.I., Kovrigina A.M. Kaposi’s sarcoma in HIV-negative patient with primary myelofibrosis. Russian journal of hematology and transfusiology. 2021;66(3):433-444. (In Russ.) https://doi.org/10.35754/0234-5730-2021-66-3-433-444
Views:
2600
Email this article 
